昭衍新藥(603127.SH)放棄昭衍生物優先受讓權和增資優先認購權
格隆匯11月18日丨昭衍新藥(603127.SH)公佈,北京昭衍生物技術有限公司(下稱“昭衍生物”)為公司和關聯方共青城子衿投資中心(有限合夥)(下稱“子衿投資”)及Blacc Management Limited(下稱“Blacc”)共同投資的公司,昭衍生物註冊資本為5億元,其中子衿投資為4.25億元、持股85%,公司投資為0.5億元、持股10%,Blacc投資為0.25億、持股5%。
昭衍生物因業務需要,現有股東子衿投資和Blacc擬將各自持有的昭衍生物的尚未認繳出資的85%和5%股權分別轉讓給JOINN Biologics(HK) Limited(下稱“昭衍生物香港”),轉讓對價參照昭衍生物經評估後的評估值進行確定,以滿足重組需求。昭衍生物在此基礎上,擬進行增資擴股,引進戰略股東北京華蓋信誠遠航醫療產業投資合夥企業(有限合夥)(下稱“華蓋醫療”),華蓋醫療擬投資5000萬美元,其中新增註冊資本1億人民幣,其餘部分計入資本公積。
昭衍新藥根據自身發展需要,經綜合考慮,決定放棄子衿投資和Blacc轉讓昭衍生物股權的優先受讓權,同時也決定放棄昭衍生物增資的優先認購權。公司放棄優先受讓權和優先認購權後,公司對昭衍生物的持股比例由10%降為8.33%。昭衍生物其他股東同時放棄增資的優先認購權,增資完成後,昭衍生物的註冊資本由5億元變更為6億元,股東變更為昭衍生物香港、華蓋醫療、昭衍新藥,持股比例分別為75%、16.67%、8.33%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.